What the DOJ’s 2026 Corporate Enforcement Policy update means for compliance teams

Learn more about the Department of Justice's 2026 update to its Corporate Enforcement Policy, and how AI-enabled communications monitoring can help you stay ahead of regulatory enforcement by detecting and flagging misconduct before a whistleblower does.

24 June 2026 3 mins read
Global Relay Icon By Ryan Thaxton

The Department of Justice's Corporate Enforcement Policy: 2026 update

DOJ releases a new, department-wide Corporate Enforcement Policy highlighting the need for proactive compliance in healthcare and life sciences.

The Department of Justice (DOJ) has released an update to its Corporate Enforcement and Voluntary Self-Disclosure Policy (CEP). The update expands the policy to the entire department, the first ever unified framework governing corporate criminal enforcement across all DOJ components. The updated policy applies to all corporate criminal matters handled by the DOJ, with the sole exception of antitrust violations. For compliance teams, it removes uncertainties about which policy applies when a disclosure implicates multiple components and whether different offices produce uneven outcomes.

One policy across all departments

Announced on March 10, 2026, the update extends the framework first introduced in May 2025 to every component and all 93 U.S. Attorney’s Offices nationwide. It supersedes the patchwork of component and district-specific self-disclosure policies that previously left companies guessing.

There are two major updates for compliance teams:

  1. Reporting is now channel-neutral: A company can self-disclose to any appropriate DOJ component, and that good-faith disclosure is still recognized if another component takes over the case.
  2. The benefit for “near miss” disclosures is reduced: The 2025 policy offered a fixed 75% reduction off the low end of the Sentencing Guidelines; the 2026 policy sets a range of 50%-75% at prosecutors’ discretion.

Disclosing earlier and cooperating fully still moves the needle for companies aiming to get ahead of an audit or whistleblower. Last year, the DOJ released a flowchart showing these three paths to favorable resolution. We’ve updated that flowchart to reflect the latest policy change and show how proactive compliance monitoring can help you achieve one of those three resolutions.

It’s still not “all or nothing”

When the DOJ first rolled out the revised CEP, then-Criminal Division head Matthew Galeotti reminded compliance teams that self-disclosure isn’t all or nothing. That principle still anchors the policy’s three-path structure:

Part I – Declination: Companies that self-disclose, fully cooperate, and remediate in a timely manner—with no aggravating circumstances—will not be prosecuted.

Part II – “Near miss:” A good-faith disclosure that falls short of full declination still earns a non-prosecution agreement, a term under three years, no monitor, and a 50–75% fine reduction.

Part III – Other resolutions: Everything else falls to prosecutorial discretion, with possible reductions up to 50%.

Why early detection is a commercial advantage

In healthcare and life sciences specifically, a qui tam complaint is filed under seal, hidden from the company it names. Part I declination requires that misconduct be “not previously known” to DOJ, so if a relator filed before you self-report, that path may already be closed, and the seal means you’d have no way of knowing. The faster your team detects potential misconduct, the more of the CEP’s benefits you can preserve.

Timing isn’t the only place proactive compliance pays off. The policy also reinforces a well-known DOJ expectation that companies retain business communications and control the use of ephemeral and personal messaging channels—controls that demonstrate meaningful remediation to the DOJ.  

Global Relay’s AI-enabled monitoring helps compliance teams detect communication risks in real time, enabling you to self-report with speed and precision, and meet DOJ expectations before external exposure. Learn more about Global Relay for Healthcare and Life Sciences.

About Article

Published 24 June 2026

About Author

Share Article